Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on March 4, 2016. The report details a corporate action regarding the company's capital structure effective as of the close of business on March 4, 2016.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a capitalization event.
- Post-Split Share Count: Approximately 858,140 shares of common stock outstanding immediately following the event.
- Reverse Split Ratio: 1-for-10.
Material Changes
The primary material change reported is the amendment of the company's second amended and restated certificate of incorporation to effect a 1-for-10 reverse stock split. This action was approved by stockholders at a special meeting on February 8, 2016, with the specific ratio authorized by the Board of Directors on February 24, 2016.
- Fractional shares resulting from the split will be settled via cash payment rather than issuance.
- Outstanding options, warrants, and convertible debt have been adjusted accordingly, with exercise and conversion prices modified to reflect the split.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the execution of the reverse split. The company issued a press release on March 4, 2016, to disclose this event under Regulation FD.
Key Facts for Investor Verification
- Verify the adjusted share count of approximately 858,140 shares post-split.
- Confirm the adjustment of exercise prices for all outstanding options, warrants, and convertible debt.
- Review the terms regarding cash payments in lieu of fractional shares.
- Check the attached Exhibit 3.1 for the full text of the Certificate of Amendment.